Sonio has today announced the official approval by the French Ministry of the Economy and Finance of the complete acquisition of shares by Samsung.
The deal closes following the company’s second wave of US Food and Drug Administration (FDA) clearance in 2024 and with Sonio reporting and workflow solution operating in multiple sites across the USA.
“Alongside Samsung Medison, we are excited to make significant strides in the maternal care industry. In addition, Sonio plans to continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare” says Cecile Brosset, chief executive officer (CEO) and co-founder of Sonio.
Established in 2020, Sonio has developed a reporting and workflow solution powered by artificial intelligence (AI) for obstetrics and gynaecology ultrasound that assists clinicians in the evaluation and documentation of ultrasound exams.
Samsung Medison CEO Kyu Tae Yoo said: “With the workforce shortages affecting the global healthcare industry, the real-time ultrasound exam guidance and quality assurance developed by Sonio is becoming more relevant to ensure high quality care. We look forward to combining Sonio’s and Samsung’s advanced engineering to enhance our ultrasound roadmap and introduce next generation AI technologies to the market. We will focus on innovations designed to enhance exam quality, efficiency, and ultimately improve patient care.”
“We are committed to support all healthcare providers and patients as we pursue our mission of providing equal access to high-end technology and quality maternal healthcare globally,” commented Brosset.
